Drugs / AC676
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05780034 | Jun 2023 → Mar 2026 overdue | B-cell neoplasm | Accutar Biotechnology Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC676 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05780034 ↗ |
| Route | Oral | “AC676 will be given orally (PO) on a 28-day cycle.” NCT05780034 ↗ |
| Target | BTK | “BTK degrader” NCT05780034 ↗ |